Although the molecular mechanism of tamoxifen action in estrogen receptor-""""""""positive"""""""" (ER+) breast cancer cells is well studied, there is little information on how tamoxifen may act in normal ER-""""""""poor"""""""" human mammary epithelial cells (HMECs). This information is critical for developing breast cancer prevention strategies with defined endpoints. To model p53 loss in the context of tamoxifen chemoprevention, we tested in vitro whether tamoxifen was able to eliminate HMECs immediately after suppression of p53 function. Surprisingly, when p53 was acutely suppressed, the resultant p53(-) HMECs underwent apoptosis when treated with clinically relevant concentrations oftamoxifen, p53(+) controls underwent growth arrest only. Induction of apoptosis correlated with a rapid reduction of Akt-1 phosphorylation, decreased expression of Bcl-2, mitochondrial depolarization, and caspase-activation. The """"""""classic"""""""" mechanism of steroid action requires the presence of ER and both transcription and translation. However, there is evidence that estrogen and perhaps antiestrogens may act through """"""""non-classic"""""""" signaling pathways. In Preliminary Data, we observed that induction of apoptosis was not induced by 4-OHT or ICI 182,780. Based on Preliminary Data we hypothesize that induction of apoptosis by tamoxifen in p53(-) HMECs may occur via a """"""""non-classic"""""""" Akt-regulated pathway. While early passage p53(-) HMECs initially exhibited tamoxifen-sensitivity, resistance rapidly developed and correlated with persistent Akt-phosphorylation, lack of mitochondrial depolarization and loss of expression of the CREB-binding protein, CBP. Observations in our model system predict that if HMECs loose p53 function in the absence of tamoxifen chemoprevention there is a high likelihood that tamoxifen-resistance will subsequently develop. SA I will test l) whether ER modulates sensitivity to tamoxifen-induced apoptosis in early passage p53(-) HMECs utilizing phage display, ER-selective peptide ligand and 2) whether tamoxifen induces apoptosis in p53 (-/-) ER-""""""""poor"""""""" mammary cells in vivo. SA II will test whether l) inhibition of Akt phosphorylation in p53(-) HMECs promotes tamoxifen-induced apoptosis and 2) Akt mediates CBP-phosphorylation. SA III will test whether tamoxifen promotes apoptosis in early passage p53(-) HEMCs by altering the ratio of Bcl-2/Bad and test the relationship between Akt phosphorylation and Bcl-2/Bad activity. Studies proposed in SAs will characterize this novel mechanism of tamoxifen-signaling and define potential biologic markers of response. Our long-term goal is to utilize this signal-transduction pathway to model novel combinations of hormonal and non-hormonal agents and then pilot these novel strategies in small-scale prevention trials utilizing markers developed in this proposal to test for response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098441-02
Application #
6771129
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Malone, Winfred F
Project Start
2003-07-03
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
2
Fiscal Year
2004
Total Cost
$308,385
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Ibarra-Drendall, Catherine; Troch, Michelle M; Barry, William T et al. (2012) Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 132:487-98
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Pilie, Patrick G; Ibarra-Drendall, Catherine; Troch, Michelle M et al. (2011) Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev 20:476-82
Vasilatos, Shauna N; Broadwater, Gloria; Barry, William T et al. (2009) CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 18:901-14
Ibarra-Drendall, Catherine; Wilke, Lee G; Zalles, Carola et al. (2009) Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study. Cancer Epidemiol Biomarkers Prev 18:1379-85
Baker Jr, Joseph C; Ostrander, Julie H; Lem, Siya et al. (2008) ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 17:1884-90
Bean, Gregory R; Bryson, Andrew D; Pilie, Patrick G et al. (2007) Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 13:6834-41
Bean, Gregory R; Ibarra Drendall, Catherine; Goldenberg, Vanessa K et al. (2007) Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:50-6
Bowie, M L; Troch, M M; Delrow, J et al. (2007) Interferon regulatory factor-1 regulates reconstituted extracellular matrix (rECM)-mediated apoptosis in human mammary epithelial cells. Oncogene 26:2017-26
Seewaldt, Victoria L; Goldenberg, Vanessa; Jones, Lee W et al. (2007) Overweight and obese perimenopausal and postmenopausal women exhibit increased abnormal mammary epithelial cytology. Cancer Epidemiol Biomarkers Prev 16:613-6

Showing the most recent 10 out of 13 publications